Log in to search using one of your social media accounts:

 

Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns
We read with great interest the study by Lei and colleagues about the impact of antiviral therapy (AVT) on survival outcomes of patients with hepatitis B virus (HBV)-associated intrahepatic cholangiocarcinoma (ICC), which concluded that the patients who received AVT (5-yr overall survival [OS], 43.0%; 5-yr relapse-free survival [RFS], 29.5%) could achieve better long-term outcomes compared to the others who revealed low (5-yr OS, 33.5%; RFS, 28.3%) and high (5-yr OS, 20.5%; RFS, 13.5%) viral levels, respectively. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 20, 2018 Category: Gastroenterology Authors: Meng Sha, Seogsong Jeong, Qiang Xia Source Type: research

Pediatric Fatty Liver Disease (PeFLD): all is not NAFLD - pathophysiological insights and approach to management
The recognition of a pattern of steatotic liver injury where histology mimicked alcoholic liver disease but alcohol consumption was denied, led to the identification of non-alcoholic fatty liver disease (NAFLD) [1] - the most common chronic liver disease in adults today. The global epidemic of obesity has been attributed to be a major factor in the pathogenesis of this condition. The pediatric community also joined the bandwagon of adult hepatology and embraced the term despite alcohol consumption, or certainly its contribution to liver disease state, being minimal pre-adolescence [2]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 19, 2018 Category: Gastroenterology Authors: Robert Hegarty, Maesha Deheragoda, Emer Fitzpatrick, Anil Dhawan Tags: Review Source Type: research

Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin versus Sorafenib for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer worldwide [1] and advanced-stage is found in 25%-70% of HCC at diagnosis with a median overall survival (OS) of only 4.2-7.9 months due to limited treatment options. [2,3] To date, sorafenib is still the only treatment shown to extend OS for advanced HCC (Ad-HCC). [4] However, low response rates [2], modest survival advantages [3], high-level heterogeneity of individual response [5] and insensitivity for population with HBV infection [6], such limitations of sorafenib prohibit its widespread use in Ad-HCC and more alternative therapies are urgently requir...
Source: Journal of Hepatology - February 19, 2018 Category: Gastroenterology Authors: Ning Lyu, Yanan Kong, Luwen Mu, Youen Lin, Jibin Li, Yaru Liu, Zhenfeng Zhang, Lie Zheng, Haijing Deng, Shaolong Li, Qiankun Xie, Rongping Guo, Ming Shi, Li Xu, Xiuyu Cai, Peihong Wu, Ming Zhao Source Type: research

Interfering with Kupffer cell replenishment: New insights into liver injury
Interferon (IFN) has slipped off the hepatology radar in recent years, but a study by Borst and colleagues in this issue of Journal of Hepatology, reminds us that IFN signalling is an integral component of the liver ’s highly coordinated response to viral infection and tissue injury. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 17, 2018 Category: Gastroenterology Authors: William Alazawi, Percy A. Knolle Tags: Editorial Source Type: research

Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: it takes three to tango
In this editorial the roles of systemic inflammation, elevated pressure in portal venous system and heart function and circulation in stable cirrhosis and decompensated cirrhosis with or without organ failures are described. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 17, 2018 Category: Gastroenterology Authors: M.J. Coenraad, R. Porcher, F. Bendtsen Source Type: research

Reply to “Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns”
We appreciate the letter from Dr. Sha and colleagues in response to our recent report on antiviral therapy (AVT) in patients with HBV-related intrahepatic cholangiocarcinoma (ICC) undergoing partial hepatectomy.[1] We would like to thank the readers for their interest in our study. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 17, 2018 Category: Gastroenterology Authors: Jun Li, Zhengqing Lei, Kui Wang, Feng Shen Tags: Letter to the Editor Source Type: research

Apoptosis of enterocytes and nitration of junctional complex proteins promote alcohol-induced gut leakiness and liver injury
Excessive amounts of alcohol intake can damage many organs or deaths in severe cases. Heavy alcohol intake is also known to cause gut leakiness, contributing to increased endotoxemia and inflammatory tissue damage in the liver and brain [1 –4]. Various pathological conditions, such as HIV infection [5–7], obesity [8], and burn injury [9], are known to increase gut leakiness and endotoxemia. In addition, binge alcohol [10] and nonalcoholic substances such as high fat diets [11] and fructose [12] can stimulate gut leakiness, leading to elevated serum endotoxin and liver inflammation. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 17, 2018 Category: Gastroenterology Authors: Young-Eun Cho, Li-Rong Yu, Mohamed A. Abdelmegeed, Seong-Ho Yoo, Byoung-Joon Song Source Type: research

Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice
Hepatic ischemia reperfusion (I/R) injury is a major complication of severe hypotension followed by fluid resuscitation, liver resection, and liver transplantation [1]. Hepatic I/R injury followed by hepatic tissue repair significantly affects post-operative liver function and survival, since insufficient liver restoration is associated with increased morbidity and mortality [2,3]. Thus, the balance between hepatocyte death and subsequent liver repair and regeneration determines the prognosis of patients with hepatic I/R injury. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 17, 2018 Category: Gastroenterology Authors: Nobuyuki Nishizawa, Yoshiya Ito, Koji Eshima, Hirotoki Ohkubo, Ken Kojo, Tomoyoshi Inoue, Joan Raouf, Per-Johan Jakobsson, Satoshi Uematsu, Shizuo Akira, Shuh Narumiya, Masahiko Watanabe, Masataka Majima Source Type: research

From the Editor ’s desk...
Excessive alcohol consumption in young people is a major public health problem worldwide. Whether alcohol consumption early in life is associated with later development of severe liver disease is uncertain. In this issue of the Journal, Hagstr öm et al. used data on alcohol consumption at conscription to military service from 43,296 men (18–20 years) in Sweden during the late 60s. During a mean follow-up of 38 years, 383 men developed severe liver disease. Alcohol consumption in people between 18 and 20 years old was associated w ith an increased risk of development of severe liver disease in a dose-respon...
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Authors: Richard Moreau, Ramon Bataller, Thomas Berg, Jessica Zucman-Rossi, Rajiv Jalan Tags: Editorial Desk Source Type: research

Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

EASL NAFLD Summit 2018, Geneva, Switzerland
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

EASL monothematic conference: Gut –liver axis, Leuven, Belgium, 2018
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

EASL membership
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

The International Liver CongressTM, Paris, France, 2018
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

Contents
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

EASL clinical school: Abdominal sonography
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

JHEP at a glance (March 2018)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

Discover the EASL app collection
(Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Source Type: research

O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis
Hepatocellular carcinoma (HCC) is the sixth-most frequent and the second-most lethal cancer worldwide, with a rising incidence in developing and industrialized countries[1]. Until now, surgery has remained the most effective treatment with curative potential. Nevertheless, most patients are still diagnosed at an advanced/late stage when surgery is no longer applicable, and display symptoms of intrahepatic and extrahepatic metastasis[2]. Few effective treatment options exist for patients with advanced HCC, with a 5 year survival rate of around only 30% –40%[3]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Authors: Fangfang Duan, Hao Wu, Dongwei Jia, Weicheng Wu, Shifang Ren, Lan Wang, Shushu Song, Xinying Guo, Fenglin Liu, Yuanyuan Ruan, Jianxin Gu Source Type: research

Recipient characteristics and morbidity and mortality after liver transplantation
Background (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 15, 2018 Category: Gastroenterology Authors: Sumeet K Asrani, Giovanna Saracino, Jacqueline G. O'Leary, Stevan Gonzales, Peter Kim, Greg McKenna, Goran Klintmalm, James Trotter Source Type: research

Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma
Although several potentially curative treatments for hepatocellular carcinoma (HCC) are known, such as liver resection and local ablation, HCC is difficult to manage, because the tumor mostly develops on a background of cirrhosis, and the limited functional reserves of the liver making their use difficult.[1] In recent years, liver transplantation (LT) has generally been considered a feasible treatment capable of simultaneously curing HCC and the underlying liver cirrhosis, with living-donor liver transplantation (LDLT) performed on select patients with HCC as a practical alternative to deceased-donor liver transplantation...
Source: Journal of Hepatology - February 13, 2018 Category: Gastroenterology Authors: Young-In Yoon, Gi-Won Song, Sung-Gyu Lee, Shin Hwang, Ki-Hun Kim, Seok-Hwan Kim, Woo-Hyoung Kang, Hwui-Dong Cho, Eun-Kyoung Jwa, Jae- Hyun Kwon, Eun-Young Tak, Varvara A. Kirchner Source Type: research

Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release
Ammonium has repeatedly been found a key factor in the pathogenesis of hepatic encephalopathy (HE) [1] and development of brain edema (BE) in acute liver failure [2]. Yet, the underlying mechanisms are still not understood in detail, specifically a mediator responsible for disturbances in the microcirculation and vasodilatation remains to be identified. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 13, 2018 Category: Gastroenterology Authors: Peter Nissen Bjerring, Esben Jannik Bjerrum, Fin Stolze Larsen Source Type: research

Prolactin improves hepatic steatosis via CD36 pathway
Non-alcoholic fatty liver disease (NAFLD) is a common public health problem affecting up to 25% of the adults around the world [1]. It is associated with a series of metabolic comorbidities. NAFLD is initially caused by an imbalance between lipid demand and supply; however, the pathogenesis of the disease also involves crosstalk between liver and extra-hepatic organs, including adipose tissue and central nervous system (CNS) [2]. By sensing and integration of the peripheral signals (such as leptin), hypothalamic arcuate nucleus (ARC) neurons in CNS can induce hepatic fatty acid oxidation [3]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 13, 2018 Category: Gastroenterology Authors: Pengzi Zhang, Zhijuan Ge, Hongdong Wang, Wenhuan Feng, Xitai Sun, Xuehui Chu, Can Jiang, Yan Wang, Dalong Zhu, Yan Bi Source Type: research

Glycogen synthase kinase 3 β promotes liver innate immune activation by restraining AMP-activated protein kinase activation
Liver inflammation triggered by ischemia reperfusion (IR) is an innate immune-dominated response, mediated by the sentinel pattern recognition receptor (PRR) system [1,2]. Danger associated molecular patterns (DAMPs) [3], such as HMGB-1, released from necrotic/stressed cells [4 –6], activates PRRs including TLRs and NLRs [7–10] to initiate the pro-inflammatory immune response. At the cellular level, macrophages, the predominant innate immune cells in livers, play a major role in reacting to DAMPs to trigger tissue inflammatory immune response. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 13, 2018 Category: Gastroenterology Authors: Haoming Zhou, Han Wang, Ming Ni, Shi Yue, Yongxiang Xia, Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski, Ling Lu, Xuehao Wang, Yuan Zhai Source Type: research

Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characters: a pilot open-lable randomized study
Despite extensive vaccination programs, chronic infection with hepatitis B virus (HBV) in children remains a serious health problem worldwide [1 –5]. Even though a benign course of chronic HBV infection during childhood has been described, 3-5% and 0.01-0.03% of chronic carriers develop cirrhosis or hepatocellular carcinoma (HCC) before adulthood [6]. Considering the whole lifetime, the risk of HCC rises to 9-24% and the incidence of cirrh osis to 2-3% per year [7]. In children, chronic hepatitis B (CHB) is characterized by its natural course, includingimmune-tolerant phase, immune-active state and inactive carrier. ...
Source: Journal of Hepatology - February 13, 2018 Category: Gastroenterology Authors: Shishu Zhu, Hongfei Zhang, Yi Dong, Limin Wang, Zhiqiang Xu, Weiwei Liu, Yu Gan, Hongmei Tang, Dawei Chen, Fuchuan Wang, Pan Zhao Source Type: research

SNX10 mediates alcohol-induced liver injury and steatosis via regulating chaperone-mediated autophagy activation.
Alcoholic liver disease (ALD) is a spectrum of disorders ranging from reversible steatosis to life-threatening and irreversible cirrhosis, and in few percent cases hepatocellular cancer [1]. Alcohol exposure induces oxidative stress and mitochondrial dysfunction, which leads to hepatocyte apoptosis, necrosis, and necroptosis, as well as hepatic inflammation. In addition, ethanol consumption disrupts lipid metabolism and subsequently accumulates excessive triglycerides in the liver, further aggravating liver injury [2]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 13, 2018 Category: Gastroenterology Authors: Yan You, Wan-Zhen Li, Sulin Zhang, Bin Hu, Yue-Xuan Li, Hai-Dong Li, Huan-Huan Tang, Qian-Wen Li, Yun-Yun Guan, Li-Xin Liu, Wei-Lian Bao, Xiaoyan Shen Source Type: research

A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses
The hepatitis B virus (HBV) is one of the most important human pathogens, causing at least 680,000 deaths each year globally due to chronic infection resulting in liver cirrhosis and hepatocellular carcinoma [1]. HBV is the prototype species of the genus Orthohepadnavirus in the family Hepadnaviridae. In humans, HBV comprises 10 genotypes named A-J [2]. Additional HBV genotypes infect Old World non-human primates (NHP), including chimpanzees, gorillas, orang-utans and gibbons [3]. Infection of humans with HBV genotypes from NHP has not been described yet. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 8, 2018 Category: Gastroenterology Authors: Breno Frederico de Carvalho Dominguez Souza, Alexander K önig, Andrea Rasche, Ianei de Oliveira Carneiro, Nora Stephan, Victor Max Corman, Pia Luise Roppert, Nora Goldmann, Ramona Kepper, Simon Franz Müller, Christof Völker, Alex Junior Souza de Souza, Source Type: research

Reply to: “Coffee consumption and decreased all-cause mortality – What is the true estimate of effect?”
We thank Chitsaz et al.1 for their interest in our work, and we are pleased to provide a point-by-point response to their comments. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 7, 2018 Category: Gastroenterology Authors: Camelia Protopopescu, Fabienne Marcellin, Dominique Salmon-Ceron, Maria Patrizia Carrieri Tags: Letter to the Editor Source Type: research

Intra-arterial Idarubicin_lipiodol without embolization in hepatocellular carcinoma: the LIDA-B phase I trial
Transarterial chemoembolization (TACE) is the standard-of-care for unresectable intermediate-stage HCC[1]. Although TACE has been widely used for several years, the procedure varies widely across centres and interventional radiologists, especially regarding chemotherapeutic agents, doses, drug-releasing vectors, and embolization agents[2]. This heterogeneity is explained by the absence of proof to clarify the mechanism by which TACE improves patient survival. Some clinicians believe that embolization plays a major role and that adding a chemotherapeutic agent does not improve efficacy. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 7, 2018 Category: Gastroenterology Authors: Boris Guiu, Jean-Louis Jouve, Antonin Schmitt, Anne Minello, Franck Bonnetain, Christophe Cassinotto, Lauranne Piron, Jean-Pierre Cercueil, Romaric Loffroy, Marianne Latournerie, Ma ëva Wendremaire, Côme Lepage, Mathieu Boulin Source Type: research

8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
Chronic infection with hepatitis B virus (HBV) represents one of the most common causes of chronic liver disease worldwide.[1 –3] Patients with chronic HBV infection may remain with low viral replication and without significant histological lesions, but a substantial proportion of them develops chronic hepatitis B (CHB) with high viral replication and active histological lesions,[1,4,5] If left untreated, CHB leads to ac cumulation of liver fibrosis and eventually progresses to cirrhosis and liver decompensation, thus associated with high morbidity and mortality. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 7, 2018 Category: Gastroenterology Authors: George V. Papatheodoridis, Vana Sypsa, George Dalekos, Cihan Yurdaydin, Florian Van Boemmel, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Nikolaos Gatselis, Onur Kesk ın, Maria Lehre Source Type: research

Reply to: ”Coffee consumption and decreased all-cause mortality - What is the true estimate of effect?”
We thank Chitsaz et al. [1] for their interest in our work, and we are pleased to provide a point-by-point response to their comments. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 7, 2018 Category: Gastroenterology Authors: Camelia Protopopescu, Fabienne Marcellin, Dominique Salmon-ceron, Maria Patrizia Carrieri Tags: Letter to the Editor Source Type: research

Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors.
Immune-modulatory therapies have dramatically improved the survival of patients with metastatic tumors[1,2]. During the development of cancer, the immune system becomes naturally “tolerant” towards cancer cells, which are seen as part of the “self”. This tolerance is maintained by immune checkpoint pathways that down-regulate immune functions, permitting cancer cells to evade immune attacks[3,4]. Monoclonal antibodies (mAb) directed against regulatory immune checkpoi nt molecules that inhibit T-cell activation enhance this anti-tumor immunity[5]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 7, 2018 Category: Gastroenterology Authors: Eleonora De Martin, Jean-Marie Michot, Barbara Papouin, St éphane Champiat, Christine Mateus, Olivier Lambotte, Bruno Roche, Teresa Maria Antonini, Audrey Coilly, Salim Laghouati, Caroline Robert, Aurélien Marabelle, Catherine Guettier, Didier Samuel Source Type: research

Coffee consumption and decreased all-cause mortality – What is the true estimate of effect?
This study presents interesting clinical data from a large French cohort of coinfected individuals. While the authors showed a protective association between elevated coffee consumption and mortality, a few points should be considered in interpreting their findings and drawing any clinical conclusion. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 6, 2018 Category: Gastroenterology Authors: Ehsan Chitsaz, Bryan Curtin, Ben Da Tags: Letter to the Editor Source Type: research

Coffee consumption and decreased all-cause mortality - What is the true estimate of effect?
This study presents interesting clinical data from a large French cohort of coinfected individuals. While the authors showed a protective association between elevated coffee consumption and mortality, a few points should be considered in interpreting their findings and drawing any clinical conclusion. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 6, 2018 Category: Gastroenterology Tags: Letter to the Editor Source Type: research

Mesenchymal stromal cell therapy for liver diseases
The therapeutic potential of mesenchymal stromal cells (MSC) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and pre-clinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterized, accumulating evidence has revealed that various trophic factors secreted by MSC play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged li...
Source: Journal of Hepatology - February 6, 2018 Category: Gastroenterology Authors: Mohammed Alfaifi, Young Woo Eom, Philip N. Newsome, Soon Koo Baik Tags: Review Source Type: research

Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide[1]. Although long highly prevalent in Asia and Africa while relatively less common in the western world, over the past three decades, HCC incidence has doubled in the United Kingdom and tripled in the United States[2,3]. Largely because of the propensity for metastasis, the 5-year survival rate of HCC patients remains poor, and approximately 600,000 HCC patients die each year[2,4]. Identifying prognostic biomarkers and treatment targets for metastatic HCC is of paramount importance. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 5, 2018 Category: Gastroenterology Authors: Jian Yu, Qing-guo Xu, Zhen-guang Wang, Yuan Yang, Ling Zhang, Jin-zhao Ma, Shu-han Sun, Fu Yang, Wei-ping Zhou Source Type: research

Reply to: “Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients”
We thank Liaw for his interest in our study that aimed to determine the potential of finite nucleos(t)ide analogue (NA) therapy in hepatitis B ‘e’ antigen (HBeAg)-negative patients with chronic hepatitis B (CHB) in a randomised controlled setting. Below, we provide clarification on the points raised in his letter. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 4, 2018 Category: Gastroenterology Authors: Thomas Berg, J örg Petersen, FINITE [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B] study authors Tags: Letter to the Editor Source Type: research

Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients
Since Hadziyannis et al [1] reported a high off-therapy HBsAg loss rate (5-year 39%) in HBeAg-negative chronic hepatitis B patients, cessation of nucleos(t)ide analogue (Nuc) as a strategy to increase subsequent HBsAg loss has been examined by several groups of investigators [2 –4]. The tenofovir (TDF) study of Berg et al [5] in this Journal is the first randomized controlled trial on this specific issue. Although the number of patient was small, this important study has provided data of well controlled head to head comparison to confirm and extend the pivotal observatio n of Hadziyannis et al [1] that stopping antiv...
Source: Journal of Hepatology - February 4, 2018 Category: Gastroenterology Authors: Yun-Fan Liaw Tags: Letter to the Editor Source Type: research

Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B
We thank Liaw et al. for their interest in our study that aimed to determine the potential of finite nucleos(t)ide analogue (NA) therapy in hepatitis B ‘e’ antigen (HBeAg)-negative chronic hepatitis B (CHB) patients in a randomised controlled setting. Below, we provide clarification on the points they raise in their letter. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 4, 2018 Category: Gastroenterology Authors: Thomas Berg, J örg Petersen, the FINITE [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B] study authors Tags: Letter to the Editor Source Type: research

The Egyptian hepatitis C programme: a model of HCV treatment intervention?
The Egyptian HCV epidemic, and the country ’s response to it, are unlike any other country to date. Egypt has a very high burden of infection and disease: Egypt ranks 5th amongst all countries for the burden of disease from viral hepatitis,[1] close to 15% of the adult population are seropositive for HCV and over four million individuals r emain viraemic.[2,3] As a lower middle-income country, Egypt is relatively poor with a gross national income per capita of $3,410 in 2016 according to the World Bank. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 3, 2018 Category: Gastroenterology Authors: M. Lemoine, G.S. Cooke Tags: Editorial Source Type: research

Corrigendum to “Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study” [J Hepatol 67 (2017) 940–949]
Inclusion of Dr Reyad Abbadi as an author. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 3, 2018 Category: Gastroenterology Authors: Christophe Bureau, Danielle Adebayo, Mael Chalret de Rieu, Laure Elkrief, Dominique Valla, Markus Peck-Radosavljevic, Anne McCune, Reyad Abbadi, Victor Vargas, Macarena Simon-Talero, Juan Cordoba, Paolo Angeli, Silvia Rosi, Stewart MacDonald, Massimo Mala Tags: Corrigendum Source Type: research

Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis?
We read with great interest the recent manuscript of Lim et al.[1] demonstrating the impact of the time to surgery on the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma (HCC). Using the propensity scoring matching method, the authors concluded that the delayed surgery (the time to surgery ≥ 3 months) does not impact the prognosis of patients with BCLC 0-A stage HCC. Heroin, we would like to propose an important issue raised in this study. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 3, 2018 Category: Gastroenterology Authors: Youliang Pei, Xiaoping Chen, Wanguang Zhang Source Type: research

Fructose and Sugar: A Major Mediator of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome, and its rising prevalence parallels the rise in obesity and diabetes. Historically thought to result from overnutrition and sedentary lifestyle, recent evidence suggests that diets high in sugar (from sucrose and/or high fructose corn syrup (HFCS)) not only increases the risk for NAFLD, but also, nonalcoholic steatohepatitis (NASH). Here we review the experimental and clinical evidence that fructose precipitates fat accumulation in the liver, due to both increased lipogenesis and impaired fat oxidation. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 3, 2018 Category: Gastroenterology Authors: Thomas Jensen, Manal F. Abdelmalek, Shelby Sullivan, Kristen J. Nadeau, Melanie Green, Carlos Roncal, Takahiko Nakagawa, Masanari Kuwabara, Yuka Sato, Duk-Hee Kang, Dean R. Tolan, Laura G Sanchez-Lozada, Hugo R. Rosen, Miguel A. Lanaspa, Anna Mae Diehl, R Tags: Review Source Type: research

No touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm
Surgical resection (SR) and radiofrequency ablation (RFA) represent two treatments of choice for the curative management of early hepatocellular carcinoma (HCC) in patients not eligible for or awaiting liver transplantation.[1 –4] In the past, several studies mainly from Eastern centers suggested that RFA was oncologically as effective as SR for solitary HCCs of less than 2 to 3 cm. Furthermore, it is associated with less procedure-related morbidity,[5–8] resulting in better cost-effectiveness[9] and quality of life. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 2, 2018 Category: Gastroenterology Authors: Kayvan Mohkam, Paul-No ël Dumont, Anne-Frédérique Manichon, Jean-Christophe Jouvet, Loïc Boussel, Philippe Merle, Christian Ducerf, Mickaël Lesurtel, Agnès Rode, Jean-Yves Mabrut Source Type: research

Pyroptosis: an inflammatory link between NAFLD and NASH with potential therapeutic implications
Non-alcoholic fatty liver disease (NAFLD) represents a major health problem Worldwide due to its high and rising prevalence, association with cardiovascular diseases, and risk for developing cirrhosis and hepatocellular carcinoma (HCC). NAFLD is classified in different degrees, from simple steatosis (overall 20-30% prevalence), which is considered “benign”, to steatohepatitis (NASH: 2-5% prevalence) and fibrosis.[1,2] The major risk factors of NAFLD include metabolic syndrome (i.e. obesity, diabetes, hypercholesterolemia and hypertriglyceridemia), sedentary lifestyle, genetic predispositions (e.g. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 2, 2018 Category: Gastroenterology Authors: Juliane I. Beier, Jesus M. Banales Source Type: research

New insights into NAFLD and Subclinical Coronary Atherosclerosis
Nonalcoholic fatty liver disease (NAFLD) is a systemic disorder that has been associated with a variety of chronic conditions including diabetes, renal disease and most significantly, cardiovascular diseases[1]. Mounting data now support a strong link between NAFLD and in particular, atherosclerotic cardiovascular disease (ASCVD) independent of known traditional risk factors[1 –3]. The importance of this association is underscored by the observation that cardiovascular disease, in general, is the leading cause of death in individuals with NAFLD[4]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 2, 2018 Category: Gastroenterology Authors: Lisa B. VanWagner Source Type: research

Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma
Liver transplantation (LT) is regarded as the best option for radical treatment in patients with very early (stage 0) or early (stage A) hepatocellular carcinoma (HCC), according to the Barcelona Clinic Liver Cancer guideline.[1 –3] Careful patient selection is important in reducing the tumor recurrence rate and maximizing the effectiveness of LT for HCC because the availability of deceased and living donor organs is limited. Thus, the Milan criteria are used as the gold standard to increase the post-transplant survival r ate of patients with HCC, with a 5-year survival rate of 70% after LT and a recurrence rate of l...
Source: Journal of Hepatology - February 2, 2018 Category: Gastroenterology Authors: Ah Yeong Kim, Dong Hyun Sinn, Woo Kyoung Jeong, Young Kon Kim, Tae Wook Kang, Sang Yun Ha, Chul Keun Park, Gyu Seong Choi, Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Min-Ji Kim, Insuk Sohn, Sin-Ho Jung, Seung Woon Paik, Won Jae Lee Source Type: research

For whom the interferons toll – TLR7 mediated boosting of innate and adaptive immunity against chronic HBV infection
Chronic hepatitis B virus infection remains a major global health issue, with an WHO estimate of about 257 million people positive for HBsAg worldwide and at risk for developing severe liver disease and hepatocellular carcinoma. Current antiviral therapies are effective in suppressing viral replication and liver inflammation and improve long-term outcomes. However, functional cure with sustained loss of HBsAg or complete elimination of the virus and its nuclear covalently closed circular DNA (cccDNA) that acts as an episomal minichromosome from hepatocytes is an infrequent event both in the setting of nucleos(t)ide (NUC) o...
Source: Journal of Hepatology - February 2, 2018 Category: Gastroenterology Authors: Bertram Bengsch, Robert Thimme Tags: Editorial Source Type: research

Fibroblast Growth Factor Receptor Inhibition induces loss of matrix MCL1 and necrosis in Cholangiocarcinoma
Cholangiocarcinoma (CCA)is a lethal hepatobiliary malignancy with limited therapeutic options [1,2]. Advances in CCA therapy will require an understanding of oncogenic signaling networks that contribute to CCA pathogenesis and can potentially be disrupted therapeutically. Like other malignancies, a cardinal feature of CCA is inhibition of cell death pathways that are engaged by oncogenic signaling pathways [3]. Members of the BCL2 gene family encode proteins that regulate the mitochondrial or intrinsic apoptotic pathway [4]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 2, 2018 Category: Gastroenterology Authors: Ayano Kabashima, Petra Hirsova, Steven F. Bronk, Matthew C. Hernandez, Mark J. Truty, Sumera Rizvi, Scott H. Kaufmann, Gregory J. Gores Source Type: research

Reply to: “Liver resection for BCLC 0-A stage hepatocellular carcinoma: Does the time to surgery not impact the prognosis”
We thank Pei et al. for the opportunity to discuss our article recently published in the Journal of Hepatology.1 Pei et al. raised the concern that the study population of our work could not represent the whole cohort of Barcelona Clinic Liver Cancer (BCLC) A stage patients because the enrolled patients with hepatocellular carcinoma in this study had limited tumor burden. They speculate that large tumors represented only a very small proportion, which makes the representativeness and credibility of our conclusion questionable. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 1, 2018 Category: Gastroenterology Authors: Chetana Lim, Chady Salloum, Daniel Azoulay Tags: Letter to the Editor Source Type: research